Pain management最新文献

Rimegepant orally disintegrating tablet for acute treatment of migraine: a plain language summary of a clinical study. 利美吉坦口腔崩解片急性治疗偏头痛：一项临床研究的简明扼要。

IF 1.4

Pain management Pub Date : 2025-05-16 DOI: 10.1080/17581869.2025.2487406

Robert Croop, Peter J Goadsby, David A Stock, Charles M Conway, Micaela Forshaw, Elyse G Stock, Richard B Lipton

引用次数: 0

Post-acute sequelae SARS-CoV-2 infection and neuropathic pain: a narrative review of the literature and future directions. 急性后SARS-CoV-2感染与神经性疼痛：文献综述及未来发展方向

IF 1.4

Pain management Pub Date : 2025-05-14 DOI: 10.1080/17581869.2025.2501521

Peter D Vu, Salahadin Abdi

{"title":"Post-acute sequelae SARS-CoV-2 infection and neuropathic pain: a narrative review of the literature and future directions.","authors":"Peter D Vu, Salahadin Abdi","doi":"10.1080/17581869.2025.2501521","DOIUrl":"https://doi.org/10.1080/17581869.2025.2501521","url":null,"abstract":"Purpose of review: Neuropathic pain is a recognized and debilitating symptom of SARS-CoV-2 infection across acute, post-acute, and long-COVID phases. Initially emerging as acute or subacute symptoms, these neuropathic manifestations can evolve into chronic conditions, with approximately 10% of all SARS-CoV-2 cases (estimated 65 million individuals globally) developing post-acute SARS-CoV-2 (PASC) neuropathic sequalae. Given the limited literature specifically addressing neuropathic pain related to PASC, a deeper understanding is needed to improve management and reduce patient burden.Recent findings: PASC symptoms are associated with disease severity, elevated body mass indexes, preexisting psychological conditions, and addiction history. Sex differences appear to influence prevalence, and the multisystem nature of PASC complicates symptom presentation, with mood disorders, fatigue, and cognitive dysfunction contributing to altered pain perception. Proposed mechanisms include immune dysregulation, persistent viral protein effects, and neuroanatomical changes. Management typically involves a multimodal approach.Summary: This review examines SARS-CoV-2 neuropathic pain across the illness trajectory, examining its pathophysiology, prevalence, and treatment. It highlights the potential for subacute neuropathic symptoms to become chronic and calls for future research to refine long-term management strategies and assess broader healthcare implications.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-11"},"PeriodicalIF":1.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological and non-pharmacological approaches to temporomandibular disorder chronic pain: a narrative review. 颞下颌紊乱慢性疼痛的药理学和非药理学方法：叙述性回顾。

IF 1.4

Pain management Pub Date : 2025-05-08 DOI: 10.1080/17581869.2025.2502311

Fanny Jogna, Adriana Graenicher A, Quentin Rey-Millet, Alexandra Groz, Jehanne De Grasset, Fabiola Stollar, Matteo Coen, Anna Faivre

{"title":"Pharmacological and non-pharmacological approaches to temporomandibular disorder chronic pain: a narrative review.","authors":"Fanny Jogna, Adriana Graenicher A, Quentin Rey-Millet, Alexandra Groz, Jehanne De Grasset, Fabiola Stollar, Matteo Coen, Anna Faivre","doi":"10.1080/17581869.2025.2502311","DOIUrl":"https://doi.org/10.1080/17581869.2025.2502311","url":null,"abstract":"Temporomandibular disorders (TMD) involve the temporomandibular joint and related structures, causing chronic pain, impaired jaw function, and reduced quality of life. TMD has multifactorial origins, including mechanical, neuromuscular, and inflammatory factors. Chronic TMD pain is difficult to manage due to its complex pathophysiology and the limited long-term effectiveness of existing treatments. A combination of pharmacological and non-pharmacological strategies is essential for optimal pain management. This narrative review provides an integrative overview of current treatments for TMD-associated chronic pain. Pharmacological options discussed include analgesics, muscle relaxants, antidepressants, anticonvulsants, and botulinum toxin injections. Non-pharmacological strategies include physical therapy, cognitive-behavioral therapy, acupuncture, and lifestyle modifications. A comprehensive literature search was conducted using PubMed, Embase.com, Cochrane, and Evidence Alerts databases through October 2024. We focused on original research articles, randomized controlled trials, narrative and systematic reviews, and meta-analyses. Effective management of chronic TMD pain requires a multidisciplinary approach tailored to individual needs. Evidence supports the integration of physical and psychological therapies into treatment plans. Future research should aim to develop targeted interventions that address underlying mechanisms of TMD pain and evaluate the long-term outcomes of noninvasive therapies.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-12"},"PeriodicalIF":1.4,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dextrose-based Lyftogt perineural injection therapy on facial muscle strength in a Bell's palsy patient - a case report. 以葡萄糖为基础的Lyftogt神经周围注射治疗对贝尔氏麻痹患者面部肌肉力量的影响- 1例报告。

IF 1.4

Pain management Pub Date : 2025-04-29 DOI: 10.1080/17581869.2025.2494975

Isabel Patricia Serrano, Daniel Wang, Rochelle Angelica A Saratan, Melecio Iii Peña, Jeimylo C de Castro

{"title":"Dextrose-based Lyftogt perineural injection therapy on facial muscle strength in a Bell's palsy patient - a case report.","authors":"Isabel Patricia Serrano, Daniel Wang, Rochelle Angelica A Saratan, Melecio Iii Peña, Jeimylo C de Castro","doi":"10.1080/17581869.2025.2494975","DOIUrl":"https://doi.org/10.1080/17581869.2025.2494975","url":null,"abstract":"Bell's palsy, a unilateral peripheral facial nerve palsy, is one of the most common acute mononeuropathies. Chronic cases persisting beyond one year present significant challenges to conventional treatment methods. Standard treatment includes steroids and antiviral medications in the acute phase, and physical therapy, various supplements such as vitamin B12 and folic acid supplementation, and injections for chronic therapy. This case report describes the effect of a unique treatment, dextrose-based Lyftogt perineural injection therapy (LPIT), in a 22-year-old Filipino male with left-sided peripheral facial nerve palsy. His condition had persisted for a duration of 13 months and was refractory to standard management. LPIT was delivered at chronic constriction points and endpoints of the facial nerve in ten different sessions. The mechanism of LPIT involves addressing glycopenia in affected nerves, reducing neurogenic inflammation, and facilitating nerve repair by enhancing the flow of nerve growth factors. Following treatment, marked improvement was observed in the functional muscle strength of the left occipitofrontalis, zygomaticus, and buccinator muscles, progressing from weak functional to functional. This case underscores LPIT's potential as an adjunct therapy for chronic Bell's palsy, adding to the limited but a growing body of evidence supporting its role in managing neuropathic conditions.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-6"},"PeriodicalIF":1.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methadone to treat chemotherapy-induced peripheral neuropathy (METACIN): study protocol. 美沙酮治疗化疗诱导的周围神经病变（METACIN）：研究方案。

IF 1.4

Pain management Pub Date : 2025-04-28 DOI: 10.1080/17581869.2025.2494495

Mathieos Belayneh, Samar Hejazi, Bruno Gagnon, Philippa Hawley

{"title":"Methadone to treat chemotherapy-induced peripheral neuropathy (METACIN): study protocol.","authors":"Mathieos Belayneh, Samar Hejazi, Bruno Gagnon, Philippa Hawley","doi":"10.1080/17581869.2025.2494495","DOIUrl":"https://doi.org/10.1080/17581869.2025.2494495","url":null,"abstract":"Rationale: Chronic chemotherapy-induced peripheral neuropathy (CIPN) affects 70% of cancer patients, causing neuropathic pain. Duloxetine is the most recommended treatment for CIPN per most guidelines. However, Methadone, an alternative and effective treatment for refractory neuropathic cancer pain has been under-recognized and under-studied in patients with CIPN.Participants: Adult patients with cancer and life expectancy greater than 12 weeks who have >grade 1 CIPN based on National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0 grading scale lasting ≥3 months beyond chemotherapy completion.Intervention: A triple-blind, double-dummy randomized controlled trial, participants randomized to either methadone or duloxetine, followed weekly over 5 weeks with dose titration.Outcomes: Primary outcome is the efficacy of methadone versus duloxetine in reducing average pain intensity from baseline to study end. Secondary outcomes include improvements in functional and quality-of-life interference. Exploratory outcomes include proportion of participants achieving ≥30% or ≥50% pain reduction, patient-reported global impression of change, incidence of adverse events, and methadone dose escalation over a 24-week follow up period.Anticipated impact: This study will determine if methadone is a viable treatment for CIPN; a very common, distressing, and debilitating condition that otherwise has limited treatment options.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05786599.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-9"},"PeriodicalIF":1.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and factors associated with cancer-related neuropathic pain among cancer patients in Nigeria - a single-center cross-sectional study. 尼日利亚癌症患者中与癌症相关的神经性疼痛的患病率和相关因素-一项单中心横断面研究

IF 1.4

Pain management Pub Date : 2025-04-25 DOI: 10.1080/17581869.2025.2494978

Ogochukwu Izuegbuna, Israel Kolawole, Saliu Oguntola, Tiwalade Woods-Ali, Oyewale Saburi, Chijioke Chijindu Adindu, Samuel Olatoke, Olawale Adebayo Olakulehin

{"title":"Prevalence and factors associated with cancer-related neuropathic pain among cancer patients in Nigeria - a single-center cross-sectional study.","authors":"Ogochukwu Izuegbuna, Israel Kolawole, Saliu Oguntola, Tiwalade Woods-Ali, Oyewale Saburi, Chijioke Chijindu Adindu, Samuel Olatoke, Olawale Adebayo Olakulehin","doi":"10.1080/17581869.2025.2494978","DOIUrl":"https://doi.org/10.1080/17581869.2025.2494978","url":null,"abstract":"Objectives: Neuropathic pain is a major challenge in supportive care management among cancer patients. This study aims to evaluate neuropathic pain in Nigerian cancer patients.Methods: This is a cross-sectional study with 126 cancer patients recruited from the University of Ilorin Teaching Hospital and are 18 years and above. Medical records were collected from their medical files and the patients. The painDETECT questionnaire (PDQ) and the numeric rating scale (NRS) were used to determine the level and form pain.Results: Neuropathic pain in the target populace of cancer patients was 23% in prevalence. The mean age of the cancer patients in the study was 53 years; 69.8% were females. A considerable association was seen between neuropathic pain and performance status (p < 0.001), morphine and pregabalin use (p < 0.001). Binary logistic regression analysis, performance status (b = 18.00, p = 0.009) and use of morphine (b = 11.52, p < 0.001) and pregabalin (b = 18.09, p < 0.001) were significantly associated with neuropathic pain. Performance status, and morphine use (p < 0.001) were associated with pain severity.Discussion: This being the first study in Nigeria, neuropathic pain incidence in Nigerian cancer patients is a work in progress. Performance status and some pain modifiers are predictors of neuropathic pain in Nigerian cancer patients.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-8"},"PeriodicalIF":1.4,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Shaping the future of geriatric chronic pain care: a research agenda for progress. 塑造老年慢性疼痛护理的未来：进展的研究议程。

IF 1.4

Pain management Pub Date : 2025-04-17 DOI: 10.1080/17581869.2025.2493609

Lisa R LaRowe, Tony Pham, Claire Szapary, Ana-Maria Vranceanu

引用次数: 0

Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. 头对头缓解：ubrogevent， rimegevent和zaveggevent在偏头痛治疗中的应用。

IF 1.4

Pain management Pub Date : 2025-04-16 DOI: 10.1080/17581869.2025.2494494

Lanfranco Pellesi, Budour Jedie, Fadia Barhum, Samah Al-Abdullah, Paolo Martelletti, Zheman Xiao

{"title":"Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment.","authors":"Lanfranco Pellesi, Budour Jedie, Fadia Barhum, Samah Al-Abdullah, Paolo Martelletti, Zheman Xiao","doi":"10.1080/17581869.2025.2494494","DOIUrl":"https://doi.org/10.1080/17581869.2025.2494494","url":null,"abstract":"Migraine, a significant cause of disability worldwide, heavily impacts daily functioning and quality of life. Despite various acute treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans, patients experience limited relief or adverse effects. This review examines the efficacy and safety of gepants - ubrogepant, rimegepant, and zavegepant - in the acute treatment of migraine. We assessed phase II and III clinical trials, focusing on clinically relevant endpoints such as pain freedom and freedom from the most bothersome symptom at two hours post-treatment. We calculated the number needed to treat (NNT) to achieve significant endpoints for each gepant. Gepants are recommended for the acute treatment of migraine in individuals who do not respond to triptan monotherapy or combination therapy, who experience only partial effectiveness, or who cannot tolerate or have contraindications to triptans. The NNT values for achieving pain freedom at two hours were 9 for rimegepant, 11 for zavegepant, and 12 for ubrogepant, which are comparable to NSAIDs such as naproxen (NNT = 11). Paracetamol, although not an NSAID, showed similar efficacy (NNT = 12). Triptans demonstrated lower NNTs, indicating higher efficacy. Gepants offer effective, well-tolerated alternatives with no significant cardiovascular risk and minimal potential for medication-overuse headache.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-6"},"PeriodicalIF":1.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of post-arthroplasty pain: a narrative review of emerging interventional treatments. 关节置换术后疼痛的处理：新兴介入治疗的叙述性回顾。

IF 1.4

Pain management Pub Date : 2025-04-01 Epub Date: 2025-04-10 DOI: 10.1080/17581869.2025.2490466

Marc Caragea, Matthew Essman, Aaron Conger, Noah Quinlan, Peter Chalmers, Zachary McCormick

引用次数: 0

Correction. 修正。

IF 1.4

Pain management Pub Date : 2025-04-01 Epub Date: 2025-02-26 DOI: 10.1080/17581869.2025.2473162

引用次数: 0